62 related articles for article (PubMed ID: 16385649)
1. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells GA; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
Cochrane Database Syst Rev; 2008 Jan; 2008(1):CD003376. PubMed ID: 18254018
[TBL] [Abstract][Full Text] [Related]
2. The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial.
Iseri K; Iyoda M; Watanabe M; Matsumoto K; Sanada D; Inoue T; Tachibana S; Shibata T
PLoS One; 2018; 13(3):e0193846. PubMed ID: 29543887
[TBL] [Abstract][Full Text] [Related]
3. Seven years' experience with alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
Ther Clin Risk Manag; 2010 Apr; 6():201-6. PubMed ID: 20463781
[TBL] [Abstract][Full Text] [Related]
4. Five-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures.
Iwamoto J; Miyata A; Sato Y; Takeda T; Matsumoto H
Ther Clin Risk Manag; 2009; 5():773-9. PubMed ID: 19851524
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Oral Alendronate Treatment in Children and Adolescents with Osteoporosis.
Unal E; Abaci A; Bober E; Büyükgebiz A
J Pediatr Endocrinol Metab; 2006 Apr; 19(4):523-528. PubMed ID: 38742779
[No Abstract] [Full Text] [Related]
6. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: Four-year randomized study - ScienceDirect.
Am J Med; 2024 Mar; ():. PubMed ID: 38702225
[No Abstract] [Full Text] [Related]
7. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells GA; Hsieh SC; Peterson J; Zheng C; Kelly SE; Shea B; Tugwell P
Cochrane Database Syst Rev; 2024 Apr; 4(4):CD003376. PubMed ID: 38591743
[TBL] [Abstract][Full Text] [Related]
8. Live imaging of osteoclast inhibition by bisphosphonates in a medaka osteoporosis model.
Yu T; Witten PE; Huysseune A; Buettner A; To TT; Winkler C
Dis Model Mech; 2016 Feb; 9(2):155-63. PubMed ID: 26704995
[TBL] [Abstract][Full Text] [Related]
9. Too Fit To Fracture: exercise recommendations for individuals with osteoporosis or osteoporotic vertebral fracture.
Giangregorio LM; Papaioannou A; Macintyre NJ; Ashe MC; Heinonen A; Shipp K; Wark J; McGill S; Keller H; Jain R; Laprade J; Cheung AM
Osteoporos Int; 2014 Mar; 25(3):821-35. PubMed ID: 24281053
[TBL] [Abstract][Full Text] [Related]
10. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
11. Blocking TNF-α with infliximab alleviates ovariectomy induced mechanical and thermal hyperalgesia in rats.
Chen BL; Li YQ; Xie DH; He QL; Yang XX
Neurol Sci; 2012 Jun; 33(3):527-33. PubMed ID: 21874299
[TBL] [Abstract][Full Text] [Related]
12. Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis.
Iwamoto J; Makita K; Sato Y; Takeda T; Matsumoto H
Osteoporos Int; 2011 Oct; 22(10):2735-42. PubMed ID: 21104227
[TBL] [Abstract][Full Text] [Related]
13. Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis.
Iwamoto J; Uzawa M; Sato Y; Takeda T; Matsumoto H
Ther Clin Risk Manag; 2009 Jun; 5(3):499-505. PubMed ID: 19707260
[TBL] [Abstract][Full Text] [Related]
14. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Yonsei Med J; 2005 Dec; 46(6):750-8. PubMed ID: 16385649
[TBL] [Abstract][Full Text] [Related]
15. Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis.
Iwamoto J; Takeda T; Ichimura S; Uzawa M
Keio J Med; 2003 Jun; 52(2):113-9. PubMed ID: 12862363
[TBL] [Abstract][Full Text] [Related]
16. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
Iwamoto J; Takeda T; Ichimura S; Matsu K; Uzawa M
J Orthop Sci; 2003; 8(4):532-7. PubMed ID: 12898306
[TBL] [Abstract][Full Text] [Related]
17. Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Clin Rheumatol; 2004 Oct; 23(5):383-9. PubMed ID: 15278749
[TBL] [Abstract][Full Text] [Related]
18. Etidronate and alendronate in the treatment of postmenopausal osteoporosis.
Beauchesne MF; Miller PF
Ann Pharmacother; 1999 May; 33(5):587-99. PubMed ID: 10369624
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates for the treatment of postmenopausal osteoporosis: clinical studies of etidronate and alendronate.
Harris ST
Osteoporos Int; 2001 Dec; 12 Suppl 3():S11-6. PubMed ID: 11846336
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
